Germline Genetic Variants Associated With CAR T-Cell Therapy Safety and Efficacy in Hematologic Malignancies
New research published in Science Immunology reveals that a patient's germline genetics significantly impact how their body responds to CAR T-cell therapy. Since every CAR T-cell product is manufactured from the patient's own cells, understanding these individual genetic markers is necessary for predicting treatment safety and efficacy. Researchers from Mass General Brigham Cancer Institute examined data from lymphoma patients treated with axicabtagene ciloleucel, focusing on how specific inherited genetic variants influence clinical outcomes.
The study highlights the role of the STXBP2 gene in inflammatory cytokine production and macrophage activation, noting that certain variants in this gene appear linked to therapy-related toxicity. Conversely, researchers identified that variants in the ADAMTSL3 gene might provide a protective effect against toxic side effects. These findings provide a new lens through which clinicians can view the variation in patient response to cellular immunotherapy.
Beyond safety, the team discovered that variations in PTPN22 are linked to improved CAR T-cell expansion, which directly contributes to the success of the treatment. Lead author Dr. Mark B. Leick explained that because each CAR T-cell product is unique to the individual, these genetic factors are fundamental to understanding the behavior of the therapy after infusion.
Dr. Marcela Maus, co-senior author of the study, noted that these insights could change how physicians approach donor selection for "off-the-shelf" CAR T-cell products. By identifying which genetic profiles lead to the best outcomes, researchers can refine the design of future augmented CAR T-cell therapies. This work offers a path toward more personalized oncology care by incorporating germline data into patient management strategies.